Finotab tablet is a preparation of Finerenone. It is a novel non-steroidal selective & highly potent mineralocorticoid receptor antagonist.Finerenone has been recently approved by the US Food and Drug Administration for the treatment of reducing the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). FINOTAB: A Novel Therapy for Cardio-Renal Protection, taking once daily blocks MR mediated sodium reabsorption and MR over activation in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, and blood vessels) tissues. As a result, it helps to reduce the progression of chronic kidney disease (CKD) and cardiovascular (CV) risks. FINOTAB is a safe and effective option without sexual side effects and less chance of hyperkalemia. It is available as 10 mg tablet. It is launched on July 14, 2025.
